Document is current
Any future updates will be listed below
-
Authors
Mensali, Nadia https://orcid.org/0000-0002-3130-4352
Köksal, Hakan
Joaquina, Sandy https://orcid.org/0009-0005-8558-9399
Wernhoff, Patrik https://orcid.org/0000-0002-8111-9841
Casey, Nicholas P.
Romecin, Paola
Panisello, Carla https://orcid.org/0000-0002-8437-4418
Rodriguez, René https://orcid.org/0000-0002-0768-7306
Vimeux, Lene
Juzeniene, Asta
Myhre, Marit R.
Fåne, Anne
Ramírez, Carolina Castilla
Maggadottir, Solrun Melkorka
Duru, Adil Doganay https://orcid.org/0000-0002-5844-913X
Georgoudaki, Anna-Maria
Grad, Iwona
Maturana, Andrés Daniel
Gaudernack, Gustav
Kvalheim, Gunnar
Carcaboso, Angel M. https://orcid.org/0000-0002-8485-426X
de Alava, Enrique https://orcid.org/0000-0001-8400-046X
Donnadieu, Emmanuel https://orcid.org/0000-0002-4985-7254
Bruland, Øyvind S.
Menendez, Pablo
Inderberg, Else Marit
Wälchli, Sébastien https://orcid.org/0000-0001-5869-1746
-
Funding
Funding for this research was provided by:
Norges Forskningsråd (316407)
Ministry of Health and Care Services | Helse Sør-Øst RHF (2020601, 2018579, 2019062)
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (FI21/00161)
- License Information
-
More Information
Article History
Received: 17 April 2022
Accepted: 25 May 2023
First Online: 8 June 2023
Competing interests
: S.W., E.M.I., and Ø.B. are inventors of the patent WO2020127734. A.M.G. and A.D.D. were not employees of Glycostem Therapeutics B.V. when their contribution for this study was performed. I.G. was not employee of Thermo Fisher Scientific when is contribution for this study was performed. P.M. is cofounder on OneChain Immunotherapeutics, a Josep Carreras Leukemia Research Institute spin-off company. The remaining authors declare no competing interests.
